SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001213900-20-029703
Filing Date
2020-10-02
Accepted
2020-10-01 20:50:24
Documents
39
Period of Report
2020-06-30

Document Format Files

Seq Description Document Type Size
1 FORM 6-K ea127324-6k_biondvax.htm 6-K 12521
2 CONDENSED INTERIM FINANCIAL STATEMENTS ea127324ex99-1_biondvax.htm EX-99.1 386302
3 MANAGEMENT DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION ea127324ex99-2_biondvax.htm EX-99.2 34955
4 DESCRIPTION OF RISK FACTORS ea127324ex99-3_biondvax.htm EX-99.3 425430
  Complete submission text file 0001213900-20-029703.txt   2474848

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE FILE bvxv-20200630.xml EX-101.INS 334565
6 XBRL SCHEMA FILE bvxv-20200630.xsd EX-101.SCH 41483
7 XBRL CALCULATION FILE bvxv-20200630_cal.xml EX-101.CAL 35392
8 XBRL DEFINITION FILE bvxv-20200630_def.xml EX-101.DEF 109869
9 XBRL LABEL FILE bvxv-20200630_lab.xml EX-101.LAB 184334
10 XBRL PRESENTATION FILE bvxv-20200630_pre.xml EX-101.PRE 138742
Mailing Address 14 EINSTEIN ST. NES-ZIONA L3 74036
Business Address 14 EINSTEIN ST. NES-ZIONA L3 74036 972-8-9302529
BiondVax Pharmaceuticals Ltd. (Filer) CIK: 0001611747 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-37353 | Film No.: 201217820
SIC: 2836 Biological Products, (No Diagnostic Substances)